Skip to main content

Biohaven Pharma to continue late-stage study of Alzheimer's treatment

Biohaven Pharmaceutical said on Friday it would continue with a late-stage study of its experimental Alzheimer's treatment on the recommendation of an independent data-monitoring committee based on an interim analysis of results.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.